Eltrombopag

Generic Name: Eltrombopag

Brand Names: Promacta, Revolade

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₂₂N_₄O_₄

CAS Number: 496775-61-2

Unique Ingredient Identifier: S56D65XJ9G

Background: Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also bee...

Indication: Thrombopoietin receptor agonists are pharmaceutical agents that stimulate platelet production in the bone marrow. In this, they differ from the previously discussed agents that act by attempting to curtail platelet destruction.

Associated Conditions: Chronic immune thrombocytopenia, Severe Aplastic Anemia (SAA), Thrombocytopenia

Associated Therapies: First-line Therapy

Clinical Trials

A Study to Assess the Efficacy and Safety of Eltrombopag as a Rescue of Isolated Chemotherapy-induced Thrombocytopenia

Phase 3

Conditions: Solid Tumor

Interventions: Drug: Placebo
Drug: Eltrombopag

First Posted Date: 2014-03-21

Last Posted Date: 2017-10-24

Lead Sponsor: Chang Gung Memorial Hospital

Target Recruit Count: 83

Registration Number: NCT02093325

Locations: 🇨🇳
Department of Obstetrics & Gynecology and Department of Oncology Chang Gung Memorial Hospital, Chiayi City, Taiwan
🇨🇳
Division of Gynecologic Oncology, Department of Obstetrics & Gynecology and Division of Oncology Chang Gung Memorial Hospital, Linkou, Taiwan
🇨🇳
Department of Obstetrics & Gynecology Chang Gung Memorial Hospital, Kaohsiung, Taiwan

Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)

Phase 2

Terminated

Conditions: Leukemia

Interventions: Drug: Eltrombopag
Drug: Decitabine

First Posted Date: 2013-12-13

Last Posted Date: 2020-01-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 6

Registration Number: NCT02010645

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Eltrombopag for Enhancing Platelet Engraftment in Pediatric Patients Undergoing Cord Blood Transplantation

Phase 2

Conditions: Pediatric Patients Undergoing Allogeneic Cord Blood Transplantation.

Interventions: Drug: eltrombopag

First Posted Date: 2013-09-12

Last Posted Date: 2015-06-16

Lead Sponsor: moshe yeshurun

Target Recruit Count: 20

Registration Number: NCT01940562

Locations: 🇮🇱
Hadassah hospital, Jerusalem, Israel
🇮🇱
Schneider Children's Medical Center of Israel, Petah Tikva, Israel

Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: Eltrombopag
Drug: Hypomethylating Agent (HMA)

First Posted Date: 2013-07-09

Last Posted Date: 2020-02-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 29

Registration Number: NCT01893372

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Extended Dosing With Eltrombopag for Severe Aplastic Anemia

Phase 2

Completed

Conditions: Severe Aplastic Anemia (SAA)

Interventions: Drug: Eltrombopag

First Posted Date: 2013-07-03

Last Posted Date: 2023-04-25

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 40

Registration Number: NCT01891994

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

A Safety and Efficacy Study of Eltrombopag in Subjects With AML

Phase 2

Completed

Conditions: Acute Leukaemia

Interventions: Drug: Daunorubicin
Drug: Cytarabine
Drug: Placebo
Drug: Eltrombopag

First Posted Date: 2013-07-02

Last Posted Date: 2019-09-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 148

Registration Number: NCT01890746

Locations: 🇷🇺
Novartis Investigative Site, Tula, Russian Federation

Safety and Efficacy of Eltrombopag at Escalated Doses

Phase 2

Completed

Conditions: Immune Thrombocytopenia
Platelet Disorder

Interventions: Drug: Placebo
Drug: Eltrombopag

First Posted Date: 2013-06-18

Last Posted Date: 2019-06-11

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 35

Registration Number: NCT01880047

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States

Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C

Phase 2

Terminated

Conditions: Thrombocytopenia
Hepatitis C

Interventions: Drug: Eltrombopag

First Posted Date: 2013-04-01

Last Posted Date: 2019-11-13

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 7

Registration Number: NCT01821625

Locations: 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States

Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia.

Phase 2

Completed

Conditions: Thrombocytopenia

Interventions: Drug: Eltrombopag

First Posted Date: 2013-02-13

Last Posted Date: 2021-06-11

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 10

Registration Number: NCT01791101

Locations: 🇮🇹
UO Ematologia con trapianto-Università degli Studi di Bari Aldo Moro, Bari, Italy
🇮🇹
Divisione di Ematologia - Ospedali Riuniti, Bergamo, Italy
🇮🇹
La Maddalena Casa di Cura di Alta Specialità Dipartimento Oncologico di III Livello, Palermo, Italy

and more 12 locations

Eltrombopag Phase III Study In Chinese Chronic ITP Patients

Phase 3

Completed

Conditions: Purpura, Thrombocytopenic, Idiopathic and Hepatitis C

Interventions: Drug: placebo
Drug: eltrombopag

First Posted Date: 2013-01-08

Last Posted Date: 2019-12-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 155

Registration Number: NCT01762761

Locations: 🇨🇳
Novartis Investigative Site, Tianjin, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy